The firm is a U.S.-focused therapeutics venture studio that translates academic discoveries into venture- and pharmaceutical-ready drug development programs. Backed by a specialist life sciences investor and supported by strategic industry partners, the firm combines company creation, scientific development, and very early-stage investment capabilities. The firm works closely with academic institutions to identify promising discoveries, form new biotechnology companies, and advance programs toward milestones suitable for institutional financing. The firm currently focuses primarily on U.S.-based opportunities while expanding its activities into the UK and Israel.  

The firm invests exclusively in traditional therapeutics and targets programs at the earliest stages of development, with clinical-stage assets generally considered too advanced for its model. The firm is broadly modality-agnostic but has a preference for established therapeutic modalities such as small molecules and biologics. Areas of particular interest include oncology, kidney disease, fibrosis, immunology and inflammation, and neuroscience/CNS. The firm remains open to other indications when programs address compelling unmet medical needs and have substantial commercial potential.  

From a company and management team perspective, the firm does not impose strict requirements and is specifically structured to work with academic founders before a conventional management team has been assembled. Academic investigators may serve as scientific founders while the firm’s internal leadership and development team provide interim executive and operational support. The firm works hands-on to advance scientific programs, establish new companies, and prepare them for subsequent institutional financing and continued development. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A corporate venture capital arm of a global pharmaceutical company is actively identifying next-generation healthcare technologies and emerging growth opportunities. Operating independently from the parent company’s traditional business development activities, the firm takes a primarily financially driven investment approach. The firm focuses on Seed, early-, and mid-stage companies while remaining open to select Pre-Seed opportunities.  

The firm invests globally across Asia, North America, and Europe, with investment sizes tailored to each company’s stage and financing needs. The firm invests across three broad themes: restoration and enhancement of human biological functions, infectious disease eradication, and technologies that strengthen the healthcare value chain. The firm’s mandate extends beyond therapeutics to include enabling technologies, healthcare infrastructure, and platform innovations that could shape future healthcare delivery and development. The firm seeks opportunities both adjacent to and beyond its parent company’s existing businesses, prioritizing breakthrough science, significant unmet medical needs, and technologies with substantial long-term growth potential.  

From a company and management team perspective, the firm seeks scientifically differentiated technologies and founders with the potential to build sustainable healthcare businesses. The firm does not require licensing rights, acquisition options, commercialization agreements, or other strategic rights as a condition of investment. The firm can provide portfolio companies with access to pharmaceutical R&D expertise, development capabilities, industry experience, and a global network. Strategic collaborations, licensing, co-development, or other transactions may be explored separately as portfolio companies mature when mutually beneficial. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An early-stage venture capital investor is focused on globally scalable technology companies with connections to Southeast Asia and the United States. The firm primarily invests at the Pre-Seed, Seed, and Pre-Series A stages, typically deploying approximately $150K–$1M per company and generally targeting ownership positions of 5–15%. A meaningful portion of the firm’s capital is allocated to life sciences and healthcare innovation. The firm leverages technical expertise, entrepreneurial experience, and international operating networks to support early-stage companies pursuing global growth. 

Within life sciences and healthcare, the firm focuses on techbio and technology-enabled healthcare innovation. Areas of interest include computational biology, artificial intelligence and machine learning, protein and RNA technologies, gene editing and CRISPR, precision therapeutics, AI-enabled drug discovery, biomaterials, regenerative medicine, tissue engineering, synthetic biology, screening and diagnostics, digital health, healthcare analytics, and health data infrastructure. The firm is comfortable investing at very early stages, including preclinical and research-stage opportunities, and is generally indication-agnostic, with additional interest in neurotechnology and neuroscience. 

From a company and management team perspective, the firm seeks ambitious founders and technically strong teams developing differentiated intellectual property and defensible technology platforms. The firm can lead or co-invest and generally seeks board participation when leading a financing. The firm actively supports portfolio companies with technology strategy, business scaling, international expansion, recruiting, and future fundraising through its network of operators, technologists, and industry experts. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a U.S.-based healthcare investment manager focused exclusively on biotechnology and biopharmaceutical companies. The firm invests across both public and private markets and has more than two decades of experience investing in life sciences. Through its dedicated private investment strategy, the firm supports emerging biotechnology companies from Seed through Series B, with initial investments typically averaging approximately $10M and significant capacity for follow-on participation. Investments are primarily structured as equity, although convertible instruments may be considered for select Seed-stage opportunities. The firm primarily targets companies in the United States and Europe. 

The firm invests exclusively in therapeutics and is broadly agnostic across modalities and disease areas. The firm evaluates small molecules, biologics, antibodies, RNA therapeutics, cell and gene therapies, and other emerging therapeutic platforms. Areas of interest include oncology, immunology, rare diseases, metabolic disorders, and other indications characterized by significant unmet medical need. The firm is comfortable investing from the preclinical stage onward and prioritizes differentiated science, strong biological rationale, and programs capable of generating meaningful clinical value. 

From a company and management team perspective, the firm seeks strong scientific founders and experienced leadership teams capable of advancing complex therapeutic programs through key clinical and value-inflection milestones. The firm can lead, co-lead, or participate in investment syndicates and may seek board representation or observer rights. The firm takes an active approach to portfolio support, working with management on financing strategy, clinical development, business development, and long-term company building. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is the corporate venture capital arm of a diversified global company with substantial healthcare operations. The firm operates through an evergreen investment model and invests globally, with particular activity across North America, Europe, and Asia. Initial investments typically range from approximately $1M–$3M, with the capacity to invest $5M or more over the life of a portfolio company. The firm pursues strategic investments that complement its parent organization’s healthcare businesses and long-term innovation priorities. 

The firm invests across pharmaceuticals, medical devices, diagnostics, digital health, bioprocessing, and other enabling healthcare technologies. Areas of particular interest include pain management, critical care, kidney disease, musculoskeletal disorders, drug delivery, patient monitoring, digital therapeutics, and technologies that improve healthcare delivery and clinical outcomes. The firm is generally stage-agnostic but tends to favor opportunities demonstrating meaningful technical validation, preclinical proof-of-concept, or early clinical data. The firm evaluates investments partly based on their potential strategic relevance to its broader healthcare capabilities. 

From a company and management team perspective, the firm invests exclusively in private companies and is comfortable partnering with early-stage teams that are still developing their leadership and operational capabilities. The firm takes a collaborative, strategic approach and can provide access to global healthcare expertise, technical and manufacturing resources, and commercial relationships. The firm generally seeks board participation or observer rights and actively supports portfolio companies with business development, strategic partnerships, product development, and long-term growth. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a venture capital investor with a global investment mandate and a significant allocation to healthcare and life sciences. The firm typically invests approximately $2.5M per company and participates in Seed through Series B financings. The firm can act as either a lead investor or co-investor and invests globally, with particular interest in opportunities across the United States, China, and Europe. The firm seeks companies with strong and defensible intellectual property that can provide meaningful downside protection and competitive differentiation. 

The firm invests across therapeutics, medical devices, diagnostics, and healthcare IT and is broadly agnostic across indications. The firm has particular interest in medical devices and cardiovascular technologies and considers devices across regulatory pathways and stages of development. Within therapeutics, the firm evaluates programs ranging from preclinical development through Phase III, while medical device and diagnostic opportunities may be considered at any development stage. The firm also evaluates healthcare technologies incorporating automation and robotics where relevant. 

From a company and management team perspective, the firm invests exclusively in privately held companies and does not impose specific management team requirements. The firm places significant emphasis on differentiated technology and strong intellectual property. The firm may seek a board seat in select circumstances but generally prefers board observer rights, allowing the firm to remain actively engaged while supporting portfolio companies alongside other investors. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is an early-stage venture capital firm based in the United States and founded by experienced healthcare, life sciences, and technology executives. The firm invests globally in companies at the intersection of science, healthcare, and advanced computing, typically participating at the Seed stage with initial investments of approximately $250K–$500K and capacity for follow-on financings. The firm takes a hands-on investment approach and works closely with portfolio companies on strategy, business development, fundraising, and operational growth.  
 
The firm invests broadly across therapeutics, diagnostics, medical devices, and healthcare technologies, with a particular focus on artificial intelligence, machine learning, computational biology, data science, and advanced analytics. Areas of interest include AI-enabled drug discovery, clinical development, precision medicine, diagnostics, and technologies that improve healthcare delivery and operations. The firm is particularly interested in opportunities where software, computational approaches, and proprietary data can create meaningful advantages in the discovery, development, or delivery of healthcare solutions.  
 
From a company and management team perspective, the firm seeks ambitious founders developing differentiated technologies with meaningful commercial potential. The firm values domain expertise and experienced management teams but also places significant emphasis on scientific innovation, technological differentiation, and the potential to build scalable businesses. The firm may act as either a lead investor or co-investor and provides active support to help portfolio companies achieve key development, financing, and commercial milestones. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.